Addressing the Continuum of Dysglycaemia and Vascular Complications in Prediabetes and Type 2 Diabetes: Need for Early and Intensive Treatment
Nadia Ghannam,Saleh Alahmed,Raed Aldahash,Naji Aljohani,Afaf Alshammary,Ashraf Amir,Abdullah Kamal,Said Khader,Mohammed Salah,Hani Shalabi,Ahmed Abdallah,Ahmed Elboghdady
DOI: https://doi.org/10.2147/DMSO.S396621
2023-01-11
Abstract:Nadia Ghannam, 1 Saleh Alahmed, 2 Raed Aldahash, 3 Naji Aljohani, 4 Afaf Alshammary, 5 Ashraf Amir, 6 Abdullah Kamal, 7 Said Khader, 8 Mohammed Salah, 9 Hani Shalabi, 10, 11 Ahmed Abdallah, 12 Ahmed Elboghdady 12 1 Ghannam Clinic, Jeddah, Saudi Arabia; 2 Almana Group of Hospitals, Dammam, Saudi Arabia; 3 Ministry of National Guard (Health Affairs) and King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; 4 King Fahad Medical City, Riyadh, Saudi Arabia; 5 Ministry of National Guard (Health Affairs), King Abdulaziz Medical City, Riyadh and King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; 6 Family Medicine International Medical Center, Jeddah, Saudi Arabia; 7 Dallah Hospital, Riyadh, Saudi Arabia; 8 Dr. Sulaiman Al Habib Medical Group, Riyadh, Saudi Arabia; 9 Cairo University, Cairo, Egypt and GNP Hospital, Jeddah, Saudi Arabia; 10 University of Jeddah, Jeddah, Saudi Arabia; 11 Dr. Soliman Fakeeh Hospital, Jeddah, Saudi Arabia; 12 Merck Serono Middle East FZ-Ltd, Jeddah, Saudi Arabia Correspondence: Nadia Ghannam, Ghannam Clinic, King Abdulaziz Road, Jeddah, 21411, Saudi Arabia, Email The onset of type 2 diabetes increases the risk of vascular complications and death. We know now that that this risk begins long before the diabetes diagnosis. Prediabetes and type 2 diabetes are not separate entities in practice and exist within a continuum of dysglycaemia and vascular risk that increases in severity over time. This excess risk requires early intervention with lifestyle therapy supported with pharmacologic antidiabetic therapy, intensified promptly where necessary throughout the duration of the diabetes continuum. Metformin is an evidence-based treatment for preventing prediabetes and improves cardiovascular outcomes in people with type 2 diabetes from diagnosis onwards. Newer agents (SGLT2 inhibitors and GLP-1 agonists) are appropriate for people presenting with type 2 diabetes and significant cardiovascular comorbidity. Additional therapies should be used without delay to achieve patients' individualised HbA1c goals and to minimise cardiovascular risk. Keywords: prediabetes, type 2 diabetes, diabetes complications, antidiabetic therapy The publication of the Diabetes Control and Complications Trial in 1993 proved conclusively that long-term hyperglycaemia in the setting of type 1 diabetes was associated with cardiorenal complications with the potential to reduce greatly both the quantity and quality of patients' lives. 1 This was also the first randomised trial to prove that intensive vs standard control of blood glucose reduced the risk of diabetes complications. The results of the UK Prospective diabetes Study (UKPDS) in 1998 showed that intensive glucose management per se (compared with diet-based treatment only) delivered significant reductions in long-term microvascular complications in people with type 2 diabetes, 2 with significant cardiovascular outcome benefits observed in patients randomised to metformin vs the diet intervention. 3 These landmark trials, together with epidemiological associations of hyperglycaemia and adverse clinical outcomes, underpinned the design of diabetes management algorithms intended to preserve long-term health among people with diabetes. Current management recommendations for type 2 diabetes include individualised HbA1c goals based on age, comorbidities, patient preferences, risk of adverse effects of treatment, and other factors. 4,5 A general recommendation to reduce HbA1c to <7.0% for most non-pregnant adults reflects observations that the risk of diabetes complications begins to increase more steeply above this level of HbA1c, although there is no lower cut-off for HbA1c that negates the risk of complications. 6,7 Concepts of "prediabetes", "intermediate hyperglycaemia", or "non-diabetic hyperglycaemia" have evolved to characterise the substantial population with markers of blood glucose that are elevated, but insufficiently to trigger the diagnosis of type 2 diabetes. In practice, there is growing recognition that the boundary between prediabetic states and clinical type 2 diabetes is arbitrary, in that it does not mark a starting point for increased risk of diabetes-associated complications. 8 In this article, we review the evidence that prediabetes and diagnosed type 2 diabetes represent a continuum of vascular risk that should be managed early and continuously. Individuals at risk of developing type 2 diabetes demonstrate a progressive increase in in -Abstract Truncated-
endocrinology & metabolism